Molecular Prosthetics and CFTR Modulators Additively Increase Secretory HCO3- Flux in Cystic Fibrosis Airway Epithelia.

Abstract

Cystic fibrosis (CF) is caused by loss-of-function mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR), an anion channel predominantly expressed on the apical membrane of epithelial cells. Reduced Cl^- and HCO₃^- secretion due to dysfunctional CFTR results in a decrease in lung function and is the leading cause of morbidity in individuals with CF. Recent therapies, known as highly effective CFTR modulator therapy (HEMT), help improve the lung function in individuals with specific CF-causing mutations by enhancing the folding, trafficking, and gating of CFTR. However, variability in HEMT responsiveness leads to suboptimal clinical outcomes in some people with CF undergoing modulator therapy. A potential strategy is to complement their function with a CFTR-independent mechanism. One possibility is the use of ion channel-forming small molecules such as amphotericin B, which has shown promise in restoring function and host defenses in CF airway disease models. Amphotericin B functions as a molecular prosthetic for CFTR and may thus complement CFTR modulators. Here, we show that cotreatment of CF airway epithelia with HEMT and amphotericin B results in greater increases in both HCO₃^- secretory flux and ASL pH compared to treatment with either agent alone. These findings suggest that coadministration of CFTR modulators and molecular prosthetics may provide additive therapeutic benefits for individuals with CF.